Research Program on Cognition and Neuromodulation Based Interventions (RP-CNBI)

基于认知和神经调节的干预研究计划（RP-CNBI）

• 批准号: 10392461
• 负责人: Benjamin Michael Hampstead
• 金额: $ 87.67万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-04-15 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10392461
• 关键词: Address; Alzheimer' s Disease; Alzheimer' s disease related dementia; Area; Clinical; Clinical Trials; Cognition; Consensus; Data; Developing Countries; Development; Elderly; Environment; Equipment; Evaluation; Faculty; Funding; Geography; Goals; Health; Healthcare Systems; Infrastructure; International; Internet; Intervention; Intervention Studies; Knowledge; Learning; Mentors; Mentorship; Meta-Analysis; Methodology; Michigan; Outcome; Outcome Measure; Pharmacology; Positioning Attribute; Postdoctoral Fellow; Program Accessibility; Research; Research Personnel; Resources; Role; Time; Training; Translations; Travel; Treatment outcome; Underserved Population; Universities; Wages; analog; base; clinically relevant; indexing; interest; meetings; neuroimaging; neuroregulation; next generation; post-COVID-19; programs; ranpirnase; repository; success; treatment planning; treatment trial; virtual

Abstract Project description: The NIA’s Alzheimer’s disease and related dementia (ADRD) Milestone 8 focuses on the development and translation of non-pharmacologic interventions and is particularly timely given four facts. First, existing pharmacologic agents have shown limited success. Second, the number of older adults with ADRD is rapidly increasing. Third, mounting evidence indicates that non-pharmacologic interventions can enhance cognition and everyday functioning, potentially delaying clinical decline. Fourth, no Milestone 8 goals have been accomplished to date. Thus, the primary goals of the proposed Research Program on Cognition and Neuromodulation Based Interventions (RP-CNBI) are to create a sustainable and robust infrastructure (Goal 1), provide thorough training to the next generation of ADRD researchers (Goal 2), and develop consensus statements and centralized analytic platforms (Goal 3). Infrastructure will include access to well characterized older adults with ADRD, a neuroimaging platform that facilitates treatment planning and outcome evaluation, cutting-edge equipment, a tele-video-health platform, treatment and outcome measure repositories, dedicated staff to support studies, and pilot funding. Training provides a mixture of didactic and experiential- based learning, including mentorship from an international panel of experts in cognition-oriented treatments (COTs) and neuromodulation, and both salary support and travel funds for junior faculty and post-doctoral fellows. We will hold two consensus meetings that establish practice standards and identify knowledge gaps in years 2 (focused on COTs) and 5 (focused on neuromodulation), which directly address Milestone 8A. To provide empirical support for these meetings, we will refine a beta-version of a centralized repository of COT trials, known as CogTale, and develop a neuromodulation-based analogue that will be known as NeuroTale. These repositories contain key methodological and outcome details of relevant clinical trials and automatically calculate quality indices and effect sizes used to perform automated meta-analyses on selected data. The RP- CNBI is extremely well positioned for success given the outstanding research environment at the University of Michigan, including the NIA P30 funded Michigan Alzheimer’s Disease Research Center, and VA Ann Arbor Healthcare System. The PI’s role as vice-chair (ascending to chair in 2021) of the Alzheimer’s Association Non-pharmacologic Intervention Professional Interest Area (NPI-PIA) expands the Program’s reach by making collaborative and mentoring opportunities available to a wide range of professionals interested in ADRD, especially those from underserved populations and developing nations. Although physically located at the University of Michigan, the RP-CNBI leverages the post COVID-19 integration of virtual (tele-/video-/internet- based) to create a collaborative, widely-accessible program that is agnostic to geography. The combination of these resources will enhance methodologic rigor, training, and access to resources necessary for high-quality non-pharmacologic intervention research, collectively enhancing Milestones 8A-E.

抽象的 项目描述：NIA 的阿尔茨海默病和相关痴呆 (ADRD) 里程碑 8 重点关注 鉴于四个事实，非药物干预措施的开发和转化尤其及时。 首先，现有的药物治疗效果有限；其次，老年人的数量有限。 第三，越来越多的证据表明非药物干预措施可以改善 ADRD。 增强认知和日常功能，可能延缓临床衰退第四，没有里程碑 8 目标。 因此，迄今为止，拟议的认知研究计划的主要目标已经实现。 和基于神经调节的干预措施（RP-CNBI）旨在创建可持续且强大的基础设施 （目标 1），为下一代 ADRD 研究人员提供全面的培训（目标 2），并开发 共识声明和集中分析平台（目标 3）。 描述患有 ADRD 的老年人，这是一个促进治疗计划和结果的神经影像平台 评估、尖端设备、远程视频健康平台、治疗和结果测量存储库、 专门的工作人员支持研究和试点资金提供了教学和体验的结合。 基于学习，包括来自认知导向治疗的国际专家小组的指导 （COT）和神经调节，以及初级教师和博士后的工资支持和差旅费 我们将举行两次共识会议，以建立实践标准并确定知识差距。 第 2 年（重点关注 COT）和第 5 年（重点关注神经调节），直接解决里程碑 8A。 为这些会议提供经验支持，我们将完善 COT 集中存储库的 beta 版本 试验，称为 CogTale，并开发一种基于神经调节的类似物，称为 NeuroTale。 这些存储库包含相关临床试验的关键方法和结果详细信息，并自动 计算用于对选定数据执行自动荟萃分析的质量指数和效应大小。 鉴于英国大学卓越的研究环境，CNBI 处于取得成功的绝佳位置。 密歇根州，包括 NIA P30 资助的密歇根阿尔茨海默病研究中心和 VA 安娜堡 医疗保健系统 PI 作为阿尔茨海默病协会副主席（2021 年升任主席）的角色 非药物干预专业兴趣领域 (NPI-PIA) 通过使 为对 ADRD 感兴趣的广泛专业人士提供协作和指导机会， 特别是那些来自服务不足的人群和发展中国家的人，尽管他们实际上位于世界各地。 密歇根大学 RP-CNBI 利用后 COVID-19 整合虚拟（电话/视频/互联网） 基于）创建一个协作的、可广泛访问的程序，该程序与地理位置无关。 这些资源将提高方法的严谨性、培训和获得高质量所需资源的机会。 非药物干预研究，共同加强里程碑 8A-E。